IP Library Granted Patent US 8,859,551
Granted Patent B2
US 8,859,551 · App. 13/775,784 · Granted Oct 14, 2014

Compounds, formulations, and methods for treating or preventing inflammatory skin disorders

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,859,551
App. No.
13/775,784
Granted
Oct 14, 2014
Kind
B2
Abstract

In methods, compounds, and topical formulations for treatment of inflammatory skin disorders incorporating compounds represented by the formulas below: wherein each of R 1 , R 2 , and R 3 is independently hydrogen, hologen, alkyl, or alkoxy; each of R 4 and R 5 is independently hydrogen, alkyl, or alkoxy; and each of R 6 and R 7 is independently hydrogen, nitro, alkyl, or alkoxy; wherein each of A 1 , A 3 , and A 4 is independently hydrogen or alkyl; and A 2 is independently hydrogen or hydroxy; and wherein each of B 1 , B 2 , and B 3 is independently hydrogen, hydroxy, or alkoxy; and each of B 4 and B 5 is independently hydrogen or alkyl, applying such compounds topically as sprays, mists, aerosols, solutions, lotions, gels, creams, ointments, pastes, unguents, emulsions, and suspensions to treat inflammatory skin disorders and the symptoms associated therewith.

Claims (4)

1. A method of reducing the severity of one or more symptoms of an inflammatory dermatologic disorder related to the skin in a subject, the method comprising topically administering to the skin of a subject in need of such reduction an effective amount of brimonidine or a pharmaceutically acceptable salt thereof.

2. The method of claim 1 , wherein the method comprises topically administering brimonidine tartrate.

3. A method of reducing the severity of an inflammatory dermatologic disorder related to the skin in a subject, the method comprising topically administering to the skin of a subject in need of such reduction an effective amount of brimonidine or a pharmaceutically acceptable salt thereof.

4. The method of claim 3 , wherein the method comprises topically administering brimonidine tartrate.

Assignments (4)
CHANGE OF ADDRESS Recorded Jun 28, 2022
From: GALDERMA HOLDING SA
To: GALDERMA HOLDING SA
Reel/Frame 060541/0374 →
CHANGE OF NAME Recorded Dec 31, 2020
From: NESTLÉ SKIN HEALTH S.A.
To: GALDERMA HOLDING SA
Reel/Frame 054899/0803 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 8, 2016
From: GALDERMA LABORATORIES, L.P.
To: NESTLE SKIN HEALTH S.A.
Reel/Frame 039363/0320 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 5, 2014
From: GALDERMA LABORATORIES INC.
To: GALDERMA LABORATORIES, L.P.
Reel/Frame 034105/0937 →